|drug1269||Favipiravir Combined With Tocilizumab Wiki||1.00|
|D014777||Virus Diseases NIH||0.11|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
Description: The proportion of subjects undergoing DLT eventsMeasure: Safety evaluation- proportion of subjects undergoing DLT events Time: Days 1 to 7
Description: The number of presence subjects that develop of anti-durg antibody (immunogenicity)Measure: Anti-drug antibody Time: pre-infusion and Days 15, day 29, day 57, and day 92
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports